254 results match your criteria: "Milan F.C.; and the Novartis Institutes for BioMedical Research[Affiliation]"

Attitudes towards Vaccinations in a National Italian Cohort of Patients with Inflammatory Bowel Disease.

Vaccines (Basel)

October 2023

Gastroenterology and Endoscopy Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.

Background: The vaccination status of patients with inflammatory bowel disease (IBD) should be investigated before starting any treatment, and patients should eventually be vaccinated against vaccine-preventable diseases (VPDs). Patients with IBD may have suboptimal vaccination rates. The aim of this study was to evaluate the vaccination coverage, attitude towards vaccinations, and determinants among an Italian cohort of patients with IBD.

View Article and Find Full Text PDF
Article Synopsis
  • A significant number of myelofibrosis patients stop using ruxolitinib within the first 5 years due to treatment failure, highlighting the need for early identification of those at risk.* -
  • A study analyzed data from 889 patients and found that factors like low platelet count, low hemoglobin, and certain disease types increase the likelihood of stopping ruxolitinib treatment early.* -
  • A new prognostic model called STR-PM was developed to categorize patients into low, intermediate, and high-risk groups for early treatment failure, suggesting that those in higher risk categories might benefit from alternative treatments.*
View Article and Find Full Text PDF

Drug-Coated Balloon Angioplasty for De Novo Lesions on the Left Anterior Descending Artery.

Circ Cardiovasc Interv

December 2023

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy (M.G., A.S., M.C., L.N., P.P.L., G.M., A.O., F.C., D.R., G.G., O.C., G.G.S., G.C., B.R., A.M., A.C.).

Article Synopsis
  • Drug-coated balloons (DCB) show promise for treating de novo lesions in large vessels, but there is limited evidence on their effectiveness compared to drug-eluting stents (DES).
  • A study comparing 147 patients treated with DCB to 701 patients receiving DES found no significant difference in target lesion failure rates after 2 years.
  • After adjusting for patient characteristics, DCB treatment was associated with a significantly lower risk of target lesion failure, primarily due to reduced need for revascularization.
View Article and Find Full Text PDF
Article Synopsis
  • Alzheimer's disease affects memory and brain health and researchers are studying how the bacteria in our gut may play a role in it.
  • A study was done where scientists gave special bacteria from Alzheimer's patients to healthy young rats to see if it would affect their behavior and memory.
  • The results showed that the rats had memory problems that matched what was seen in the patients, suggesting that the gut bacteria can influence symptoms of Alzheimer's disease.
View Article and Find Full Text PDF

Patients with resected stage IIB/C melanoma have high recurrence risk, similar to those with resected stage IIIA/B disease. The phase 3, double-blind CheckMate 76K trial assessed 790 patients with resected stage IIB/C melanoma randomized 2:1 (stratified by tumor category) to nivolumab 480 mg or placebo every 4 weeks for 12 months. The primary endpoint was investigator-assessed recurrence-free survival (RFS).

View Article and Find Full Text PDF

Women with obstructive coronary artery disease (CAD) have a relatively lower quality of life (QoL) compared to men, but our understanding of sex differences in QoL in ischemia with no obstructive coronary artery disease (INOCA) is limited. We conducted a survey of patient members of INOCA International with an assessment of self-reported health measures. Functional capacity was retrospectively estimated using the Duke Activity Status Index (DASI), assessing levels of activities performed before and after INOCA symptom onset.

View Article and Find Full Text PDF

Bariatric surgery is associated with a postoperative reduction of 25(OH) vitamin D levels (25(OH)D) and with skeletal complications. Currently, guidelines for 25(OH)D assessment and vitamin D supplementation in bariatric patients, pre- and post-surgery, are still lacking. The aim of this work is to analyse systematically the published experience on 25(OH)D status and vitamin D supplementation, pre- and post-surgery, and to propose, on this basis, recommendations for management.

View Article and Find Full Text PDF

CRISPR-Cas9 Editing of the and Promoters to Treat Sickle Cell Disease.

N Engl J Med

August 2023

From St. Jude Children's Research Hospital, Memphis, TN (A.S., J.S.H., Y.Z.); Memorial Sloan Kettering Cancer Center, New York (J.-J.B., M.C.); the Novartis Institutes for BioMedical Research, Cambridge, MA (P.B., M.A., A.L., X.Z., S.C., T.M., Y.Y., Y.L., J.Y., V.W.C.Y., S.C.S., S.D.V.); University of Chicago Medicine, Chicago (R.P., J.L.L.); Children's Hospital Los Angeles, Los Angeles (N.K.); IRCCS San Raffaele Hospital, Milan (F.C.); and the Novartis Institutes for BioMedical Research, Basel, Switzerland (U.N.).

Background: Sickle cell disease is caused by a defect in the β-globin subunit of adult hemoglobin. Sickle hemoglobin polymerizes under hypoxic conditions, producing deformed red cells that hemolyze and cause vaso-occlusion that results in progressive organ damage and early death. Elevated fetal hemoglobin levels in red cells protect against complications of sickle cell disease.

View Article and Find Full Text PDF
Article Synopsis
  • Scientists studied over 176,000 people to see how certain genes might protect against Parkinson's disease (PD) and Alzheimer's disease (AD).
  • They found that specific types of a gene called HLA could help reduce the risk of these diseases and lower harmful proteins in the brain.
  • This suggests that our immune system might help protect us from PD and AD, which could lead to new treatments in the future.
View Article and Find Full Text PDF

A simple and robust nanosystem for photoacoustic imaging of bladder cancer based on α5β1-targeted gold nanorods.

J Nanobiotechnology

August 2023

Tumor Biology and Vascular Targeting Unit, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Via Olgettina 58, 20132, Milan, Italy.

Background: Early detection and removal of bladder cancer in patients is crucial to prevent tumor recurrence and progression. Because current imaging techniques may fail to detect small lesions of in situ carcinomas, patients with bladder cancer often relapse after initial diagnosis, thereby requiring frequent follow-up and treatments.

Results: In an attempt to obtain a sensitive and high-resolution imaging modality for bladder cancer, we have developed a photoacoustic imaging approach based on the use of PEGylated gold nanorods (GNRs) as a contrast agent, functionalized with the peptide cyclic [CphgisoDGRG] (Iso4), a selective ligand of α5β1 integrin expressed by bladder cancer cells.

View Article and Find Full Text PDF
Article Synopsis
  • This study evaluates the usability and preference of self-injection devices for biologic drugs SB4 and SB5 compared to traditional injectors like Enbrel and Humira.
  • A systematic review looked at various studies, including surveys and clinical observations with input from healthcare professionals and patients in rheumatology, gastroenterology, and dermatology.
  • Findings show that SB4 and SB5 were preferred for their user-friendly features, such as button-free design and clear feedback during injection, which can enhance treatment adherence and should guide future medical device development.
View Article and Find Full Text PDF

Detection and treatment of patients with familial hypercholesterolemia (FH) starting from childhood is fundamental to reduce morbidity and mortality. The activity of National realities such as the LIPIGEN (LIpid transPort disorders Italian GEnetic Network) Paediatric Group, founded in 2018, is a milestone in this context. The aim of this exploratory survey, conducted in October 2021 among Italian lipid clinics included in the LIPIGEN Paediatric Group, was to investigate the current clinical approach in the management and treatment of paediatric patients with suspected FH.

View Article and Find Full Text PDF

Background: Organ perfusion technology is increasingly used in many countries, with a focus, however, on the Western world. This study investigates the current international trends and obstacles to the broader routine implementation of dynamic perfusion concepts in liver transplantation.

Methods: A web-based anonymous survey was launched in 2021.

View Article and Find Full Text PDF

Purpose: In myelodysplastic syndromes (MDS), severe thrombocytopenia is associated with poor prognosis. This multicenter trial presents the second-part long-term efficacy and safety results of eltrombopag in patients with low-risk MDS and severe thrombocytopenia.

Methods: In this single-blind, randomized, placebo-controlled, phase-II trial of adult patients with International Prognostic Scoring System low- or intermediate-1-risk MDS, patients with a stable platelet (PLT) count (<30 × 10/mm) received eltrombopag or placebo until disease progression.

View Article and Find Full Text PDF
Article Synopsis
  • The DESTINY-CRC01 trial tested trastuzumab deruxtecan (T-DXd) for patients with HER2-expressing metastatic colorectal cancer (mCRC) who had previously undergone at least two treatments.
  • The primary endpoint was the objective response rate (ORR), which was 45.3% in cohort A (HER2-positive patients), while no responses were observed in cohorts B and C.
  • Safety results indicated that the most common severe side effects included decreased neutrophil count and anemia, with some cases of drug-related lung disease, supporting further research on T-DXd's effectiveness in HER2-positive mCRC.
View Article and Find Full Text PDF

Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the most commonly used regimen for the upfront treatment of diffuse large B-cell lymphoma (DLBCL). However, it is associated with cardiotoxicity, especially in older patients. Substituting doxorubicin with non-PEGylated liposomal doxorubicin (R-COMP) may reduce the risk of cardiac events, but its efficacy has never been demonstrated in prospective trials.

View Article and Find Full Text PDF

Purpose: To establish consensus among experts in lens and refractive surgery to guide general ophthalmologists on issues related to presbyopia-correcting intraocular lenses (IOLs).

Design: A modified Delphi method to reach a consensus among experts.

Methods: A steering committee formulated 105 relevant items grouped into four sections (preoperative considerations, IOL selection, intraoperative considerations, and postoperative considerations).

View Article and Find Full Text PDF

Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer.

N Engl J Med

May 2023

From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy).

Background: Prospective data on the risk of recurrence among women with hormone receptor-positive early breast cancer who temporarily discontinue endocrine therapy to attempt pregnancy are lacking.

Methods: We conducted a single-group trial in which we evaluated the temporary interruption of adjuvant endocrine therapy to attempt pregnancy in young women with previous breast cancer. Eligible women were 42 years of age or younger; had had stage I, II, or III disease; had received adjuvant endocrine therapy for 18 to 30 months; and desired pregnancy.

View Article and Find Full Text PDF

Stage-specific therapy for hypertrophic cardiomyopathy.

Eur Heart J Suppl

May 2023

Cardiomyopathy Unit, Cardiothoracovascular Department, Careggi University Hospital, Largo Brambilla, 3 50134 Florence, Italy.

Hypertrophic cardiomyopathy (HCM) is the most common inherited myocardial disease and is defined by otherwise unexplained left ventricular hypertrophy. The main complications include heart failure and arrhythmias such as atrial fibrillation and ventricular arrhythmias. Current treatment rests on septal reduction therapies, prevention of sudden cardiac death through implantable cardioverter defibrillator, and use of drugs such as beta-blockers, calcium antagonists, or amiodarone.

View Article and Find Full Text PDF

Diagnostic and prognostic electrocardiographic features in patients with hypertrophic cardiomyopathy.

Eur Heart J Suppl

May 2023

IRCCS Istituto Auxologico Italiano, Department of Cardiology, San Luca Hospital, Piazzale Brescia 20, 20149 Milan, Italy.

The standard 12-lead electrocardiogram (ECG) represents a cornerstone for the diagnosis and evaluation of hypertrophic cardiomyopathy (HCM), the most common genetically determined heart muscle disease, due to its cost-effectiveness and wide availability. The ECG may surprisingly look normal in 4-6% of adult patients, and in less than 3% of paediatric patients, but it is abnormal in the vast majority of the remaining patients. 'Specific' features comprise pathological Q-waves, deep S-waves in V1-V3, or high R-waves in V4-V6 due to left ventricular hypertrophy with T-wave (TW) depression or negative TWs.

View Article and Find Full Text PDF

Nutritional and Lifestyle Therapy for NAFLD in People with HIV.

Nutrients

April 2023

Division of Gastroenterology and Hepatology, and Chronic Viral Illness Service, McGill University Health Centre, Montreal, QC H4A 3J1, Canada.

HIV infection and nonalcoholic fatty liver disease (NAFLD) are two major epidemics affecting millions of people worldwide. As people with HIV (PWH) age, there is an increased prevalence of metabolic comorbidities, along with unique HIV factors, such as HIV chronic inflammation and life-long exposure to antiretroviral therapy, which leads to a high prevalence of NAFLD. An unhealthy lifestyle, with a high dietary intake of refined carbohydrates, saturated fatty acids, fructose added beverages, and processed red meat, as well as physical inactivity, are known to trigger and promote the progression of NAFLD to nonalcoholic steatohepatitis, liver fibrosis, and hepatocellular carcinoma.

View Article and Find Full Text PDF